Stereotactic Body Radiotherapy for Prostate Cancer

Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.

This is a single site, non-randomized, prospective, phase IV trial of patients with organ-confined prostate cancer. Data collected will include patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal tissues,tumor recurrence data, and acute and late toxicities. Follow up data will be collected during the patient's standard office visits. The anticipated duration of this study is 5 years.

Inclusion Criteria:

• Patient age >= 18 years
• Zubrod performance status of 0-3
• T1-3 N0 M0 adenocarcinoma of the prostate
• Prostate volume ≤ 100 cc
• Signed study-specific consent form

Exclusion Criteria

• Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)
• Prostate volume > 100 cc
• Nodal involvement
• Metastatic disease
• Prior pelvic radiotherapy except as part of combination therapy for prostate cancer
• History of scleroderma
• Patients with psychiatric or addictive disorder that would preclude obtaining informed consent